JP2017531042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531042A5 JP2017531042A5 JP2017539508A JP2017539508A JP2017531042A5 JP 2017531042 A5 JP2017531042 A5 JP 2017531042A5 JP 2017539508 A JP2017539508 A JP 2017539508A JP 2017539508 A JP2017539508 A JP 2017539508A JP 2017531042 A5 JP2017531042 A5 JP 2017531042A5
- Authority
- JP
- Japan
- Prior art keywords
- body weight
- composition according
- condition
- loading dose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims 19
- 230000003442 weekly effect Effects 0.000 claims 7
- 201000008482 osteoarthritis Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000012423 maintenance Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382396.1A EP3009137A1 (en) | 2014-10-16 | 2014-10-16 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
| EP14382396.1 | 2014-10-16 | ||
| PCT/EP2015/073635 WO2016059028A1 (en) | 2014-10-16 | 2015-10-13 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531042A JP2017531042A (ja) | 2017-10-19 |
| JP2017531042A5 true JP2017531042A5 (enExample) | 2018-08-23 |
| JP6655625B2 JP6655625B2 (ja) | 2020-02-26 |
Family
ID=51844648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539508A Active JP6655625B2 (ja) | 2014-10-16 | 2015-10-13 | ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11154536B2 (enExample) |
| EP (2) | EP3009137A1 (enExample) |
| JP (1) | JP6655625B2 (enExample) |
| CN (2) | CN115154465A (enExample) |
| AR (1) | AR102295A1 (enExample) |
| CA (1) | CA2964428C (enExample) |
| CY (1) | CY1123243T1 (enExample) |
| DK (1) | DK3206684T3 (enExample) |
| ES (1) | ES2828435T3 (enExample) |
| HR (1) | HRP20201233T1 (enExample) |
| HU (1) | HUE050511T2 (enExample) |
| LT (1) | LT3206684T (enExample) |
| MX (1) | MX376725B (enExample) |
| PL (1) | PL3206684T3 (enExample) |
| PT (1) | PT3206684T (enExample) |
| RS (1) | RS60777B1 (enExample) |
| SI (1) | SI3206684T1 (enExample) |
| SM (1) | SMT202000415T1 (enExample) |
| TW (1) | TWI707678B (enExample) |
| WO (1) | WO2016059028A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109303784B (zh) * | 2018-09-30 | 2020-06-23 | 山东省文登整骨医院 | 痛风性关节炎动物模型的构建方法 |
| TWI875757B (zh) * | 2019-05-08 | 2025-03-11 | 瑞士商諾華公司 | T1dm和胰島炎治療中使用之抗cd40抗體 |
| EP4029502A1 (en) | 2021-01-15 | 2022-07-20 | Ecuphar N.V. | Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
| US12208085B2 (en) | 2022-05-31 | 2025-01-28 | Ecuphar Nv | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU773615B2 (en) * | 1997-05-05 | 2004-05-27 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| ES2137138B1 (es) | 1998-05-29 | 2000-09-16 | Esteve Labor Dr | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos. |
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| CN101175769A (zh) * | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | 用于调控血管完整性的方法和组合物 |
-
2014
- 2014-10-16 EP EP14382396.1A patent/EP3009137A1/en not_active Withdrawn
-
2015
- 2015-10-13 ES ES15778958T patent/ES2828435T3/es active Active
- 2015-10-13 CN CN202210698831.5A patent/CN115154465A/zh active Pending
- 2015-10-13 SM SM20200415T patent/SMT202000415T1/it unknown
- 2015-10-13 DK DK15778958.7T patent/DK3206684T3/da active
- 2015-10-13 CN CN201580068592.3A patent/CN107257684A/zh active Pending
- 2015-10-13 PT PT157789587T patent/PT3206684T/pt unknown
- 2015-10-13 RS RS20200943A patent/RS60777B1/sr unknown
- 2015-10-13 MX MX2017004899A patent/MX376725B/es active IP Right Grant
- 2015-10-13 US US15/518,871 patent/US11154536B2/en active Active
- 2015-10-13 PL PL15778958T patent/PL3206684T3/pl unknown
- 2015-10-13 SI SI201531302T patent/SI3206684T1/sl unknown
- 2015-10-13 HR HRP20201233TT patent/HRP20201233T1/hr unknown
- 2015-10-13 WO PCT/EP2015/073635 patent/WO2016059028A1/en not_active Ceased
- 2015-10-13 EP EP15778958.7A patent/EP3206684B1/en active Active
- 2015-10-13 CA CA2964428A patent/CA2964428C/en active Active
- 2015-10-13 HU HUE15778958A patent/HUE050511T2/hu unknown
- 2015-10-13 LT LTEP15778958.7T patent/LT3206684T/lt unknown
- 2015-10-13 JP JP2017539508A patent/JP6655625B2/ja active Active
- 2015-10-16 AR ARP150103353A patent/AR102295A1/es not_active Application Discontinuation
- 2015-10-16 TW TW104134072A patent/TWI707678B/zh active
-
2020
- 2020-08-03 CY CY20201100714T patent/CY1123243T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012193216A5 (enExample) | ||
| JP2013155188A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2014111603A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2015038135A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2017512194A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| CL2013003497A1 (es) | Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. | |
| JP2016519107A5 (enExample) | ||
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| JP2017531042A5 (enExample) | ||
| ECSP078014A (es) | Regimen de dosificacion para prasugrel | |
| JP2014504636A5 (enExample) | ||
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| HRP20201233T1 (hr) | Spoj izveden od pirazolina i njegova primjena u tjednom doznom režimu protiv upale i bola porijeklom od degenerativnog oboljenja zgloba kod sisavaca | |
| JP2017516842A5 (enExample) | ||
| JP2017061488A5 (enExample) | ||
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |